JP7502865B2 - Ｃ５ａ活性のインヒビターでの炎症性疾患の処置 - Google Patents

Ｃ５ａ活性のインヒビターでの炎症性疾患の処置 Download PDF

Info

Publication number
JP7502865B2
JP7502865B2 JP2019570986A JP2019570986A JP7502865B2 JP 7502865 B2 JP7502865 B2 JP 7502865B2 JP 2019570986 A JP2019570986 A JP 2019570986A JP 2019570986 A JP2019570986 A JP 2019570986A JP 7502865 B2 JP7502865 B2 JP 7502865B2
Authority
JP
Japan
Prior art keywords
antibody
amino acid
human
binding
ifx
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019570986A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524696A (ja
JP2020524696A5 (enExample
Inventor
レンフォン・グオ
ニールス・ツェー・リーデマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
InflaRx GmbH
Original Assignee
InflaRx GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by InflaRx GmbH filed Critical InflaRx GmbH
Publication of JP2020524696A publication Critical patent/JP2020524696A/ja
Publication of JP2020524696A5 publication Critical patent/JP2020524696A5/ja
Application granted granted Critical
Publication of JP7502865B2 publication Critical patent/JP7502865B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
JP2019570986A 2017-06-23 2018-06-13 Ｃ５ａ活性のインヒビターでの炎症性疾患の処置 Active JP7502865B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17177657.8 2017-06-23
EP17177657 2017-06-23
EP17189938 2017-09-07
EP17189938.8 2017-09-07
PCT/EP2018/065676 WO2018234118A1 (en) 2017-06-23 2018-06-13 Treatment of inflammatory diseases with inhibitors of c5a activity

Publications (3)

Publication Number Publication Date
JP2020524696A JP2020524696A (ja) 2020-08-20
JP2020524696A5 JP2020524696A5 (enExample) 2021-07-26
JP7502865B2 true JP7502865B2 (ja) 2024-06-19

Family

ID=62636193

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019570986A Active JP7502865B2 (ja) 2017-06-23 2018-06-13 Ｃ５ａ活性のインヒビターでの炎症性疾患の処置

Country Status (10)

Country Link
EP (1) EP3642230A1 (enExample)
JP (1) JP7502865B2 (enExample)
KR (1) KR20200020727A (enExample)
CN (1) CN111201241A (enExample)
AU (1) AU2018286754A1 (enExample)
CA (1) CA3066689C (enExample)
IL (1) IL271074A (enExample)
SG (1) SG11201912882QA (enExample)
TW (1) TWI786132B (enExample)
WO (1) WO2018234118A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY191668A (en) 2016-06-14 2022-07-06 Regeneron Pharma Anti-c5 antibodies and uses thereof
JP2021506241A (ja) 2017-12-13 2021-02-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ｃ５抗体組み合わせ物およびその使用
JP7617012B2 (ja) 2019-03-14 2025-01-17 モルフォシス・アーゲー Ｃ５ａＲを標的とする抗体
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
AU2020438234A1 (en) * 2020-03-27 2022-09-29 Inflarx Gmbh Inhibitors of C5a for the treatment of corona virus infection
EP4172200A4 (en) * 2020-06-24 2024-10-30 Staidson (Beijing) Biopharmaceuticals Co., Ltd. ANTIBODIES SPECIFICALLY RECOGNIZING C5A AND THEIR USES
AU2022207985A1 (en) 2021-01-13 2023-07-06 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003033528A1 (en) 2001-10-17 2003-04-24 University Of Queensland Cyclic peptides as g-protein-coupled receptor antagonists
WO2008009062A1 (en) 2006-07-21 2008-01-24 Promics Pty Ltd Treatment for intimal hyperplasia and related conditions
WO2010075257A1 (en) 2008-12-22 2010-07-01 Chemocentryx, Inc. C5ar antagonists
WO2011163640A1 (en) 2010-06-24 2011-12-29 Chemocentryx, Inc. C5ar antagonists
JP2012514465A (ja) 2009-01-08 2012-06-28 アリゲーター・バイオサイエンス・アーベー 新規なポリペプチドおよびその使用
WO2015140304A1 (en) 2014-03-20 2015-09-24 Inflarx Gmbh Inhibitors of c5a for the treatment of viral pneumonia
JP2016518331A (ja) 2013-03-14 2016-06-23 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 補体成分Ｃ５ｉＲＮＡ組成物及びその使用方法
JP2016523829A (ja) 2013-05-08 2016-08-12 ノヴォ ノルディスク アー／エス Ｃ５ａｒアンタゴニストの使用
JP2020515643A (ja) 2017-04-03 2020-05-28 インフラルクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＩｎｆｌａＲｘ ＧｍｂＨ Ｃ５ａ活性のインヒビターでの炎症性疾患の処置

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
WO1991004014A1 (en) 1989-09-21 1991-04-04 Synergen, Inc. Method for transporting compositions across the blood brain barrier
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
AUPO755097A0 (en) 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
PL3385384T3 (pl) 2004-02-12 2021-03-08 Archemix Llc Aptamerowe środki terapeutyczne użyteczne w leczeniu zaburzeń powiązanych z dopełniaczem
WO2005092366A1 (en) * 2004-03-26 2005-10-06 Promics Pty Limited TREATMENT OF NEUROLOGICAL CONDITIONS USING COMPLEMENT C5a RECEPTOR MODULATORS
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
EP3194596A1 (en) 2014-09-16 2017-07-26 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
JP6479974B2 (ja) 2014-10-15 2019-03-06 アレクシオン ファーマシューティカルズ， インコーポレイテッド 大規模エクリズマブ産生細胞培養を再現する方法
FR3030515B1 (fr) * 2014-12-23 2017-01-20 Galderma Res & Dev Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines
US20180142010A1 (en) 2015-06-26 2018-05-24 Alexion Pharmaceuticals, Inc. Method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
NZ747259A (en) 2016-04-04 2022-11-25 Chemocentryx Inc Soluble c5ar antagonists

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003033528A1 (en) 2001-10-17 2003-04-24 University Of Queensland Cyclic peptides as g-protein-coupled receptor antagonists
WO2008009062A1 (en) 2006-07-21 2008-01-24 Promics Pty Ltd Treatment for intimal hyperplasia and related conditions
WO2010075257A1 (en) 2008-12-22 2010-07-01 Chemocentryx, Inc. C5ar antagonists
JP2012514465A (ja) 2009-01-08 2012-06-28 アリゲーター・バイオサイエンス・アーベー 新規なポリペプチドおよびその使用
WO2011163640A1 (en) 2010-06-24 2011-12-29 Chemocentryx, Inc. C5ar antagonists
JP2016518331A (ja) 2013-03-14 2016-06-23 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 補体成分Ｃ５ｉＲＮＡ組成物及びその使用方法
JP2016523829A (ja) 2013-05-08 2016-08-12 ノヴォ ノルディスク アー／エス Ｃ５ａｒアンタゴニストの使用
WO2015140304A1 (en) 2014-03-20 2015-09-24 Inflarx Gmbh Inhibitors of c5a for the treatment of viral pneumonia
JP2020515643A (ja) 2017-04-03 2020-05-28 インフラルクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＩｎｆｌａＲｘ ＧｍｂＨ Ｃ５ａ活性のインヒビターでの炎症性疾患の処置

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NATURE REVIEWS, 2015, Vol.14, pp.857-877
Study NCT03001622 on Date: March 20, 2017 (v3)，ClinicalTrials.gov archive[online]，2017年3月20日，<URL: https://clinicaltrials.gov/ct2/history/NCT03001622>

Also Published As

Publication number Publication date
CA3066689A1 (en) 2018-12-27
CA3066689C (en) 2024-01-16
TWI786132B (zh) 2022-12-11
TW201904611A (zh) 2019-02-01
EP3642230A1 (en) 2020-04-29
AU2018286754A1 (en) 2019-12-19
IL271074A (en) 2020-01-30
CN111201241A (zh) 2020-05-26
JP2020524696A (ja) 2020-08-20
KR20200020727A (ko) 2020-02-26
WO2018234118A1 (en) 2018-12-27
SG11201912882QA (en) 2020-01-30

Similar Documents

Publication Publication Date Title
JP7486415B2 (ja) Ｃ５ａ活性のインヒビターでの炎症性疾患の処置
US11890349B2 (en) Treatment of inflammatory diseases with inhibitors of C5A activity
JP7502865B2 (ja) Ｃ５ａ活性のインヒビターでの炎症性疾患の処置
TWI674274B (zh) 抗體－飛諾莫接合物
CN102741283B (zh) 具有高阻断活性的抗-C5a结合部分
JP6675739B2 (ja) 新規抗ｐａｄ４抗体
KR20150031298A (ko) 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법
JP2020511469A (ja) 補体が媒介する疾患および障害を処置するための方法
JP2023518884A (ja) コロナウイルス感染の処置のためのＣ５ａのインヒビター
HK40070841A (en) Treatment of inflammatory diseases with inhibitors of c5a activity
HK40101423A (en) Treatment of inflammatory diseases with inhibitors of c5a activity
EA043076B1 (ru) Лечение воспалительных заболеваний с помощью ингибиторов активности c5a

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230727

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240226

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240404

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240521

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240607

R150 Certificate of patent or registration of utility model

Ref document number: 7502865

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150